MWNA
CTMX icon

Marshall Wace North America’s CytomX Therapeutics CTMX Stock Holding History

Marshall Wace North America’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,436
Closed -$25K – 1334
2019
Q3 		$25K Buy
+3,436
New +$33.9K ﹤0.01% 1219
2019
Q1 		– Sell
-5,589
Closed -$84K – 1617
2018
Q4 		$84K Buy
+5,589
New +$82.9K ﹤0.01% 1117

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's CTMX Position: Q4 2019 in Review

Marshall Wace North America sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 3,436 shares — an estimated $25K sold.

Marshall Wace North America first reported a position in CTMX in Q4 2018 and held it in 2 quarters. The position peaked at $84K in Q4 2018. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

  • Marshall Wace North America reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 3,436 CytomX Therapeutics shares in Q4 2019, an estimated $25K.
  • Marshall Wace North America first reported a position in CytomX Therapeutics in Q4 2018 and held it in 2 quarters.
  • Marshall Wace North America's CytomX Therapeutics position peaked at $84K in Q4 2018.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.